Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Literature DB >> 20861462

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Ayalew Tefferi¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20861462 PMCID： PMC2966368 DOI： 10.4065/mcp.2010.0502

Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616

× No keyword cloud information.

48 in total

1. Is "cure" essential in the treatment of cancer?

Authors: Ayalew Tefferi
Journal: Mayo Clin Proc Date: 2008-12 Impact factor: 7.616

2. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.

Authors: Cheng E Chee; David P Steensma; Wenting Wu; Curtis A Hanson; Ayalew Tefferi
Journal: Am J Hematol Date: 2008-08 Impact factor: 10.047

3. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Authors: Michael Lübbert; Stefan Suciu; Liliana Baila; Björn Hans Rüter; Uwe Platzbecker; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Ulrich Germing; Helmut R Salih; Filip Beeldens; Petra Muus; Karl-Heinz Pflüger; Corneel Coens; Anne Hagemeijer; Hans Eckart Schaefer; Arnold Ganser; Carlo Aul; Theo de Witte; Pierre W Wijermans
Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544

4. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities.

Authors: Olga Pozdnyakova; Patricia M Miron; Guilin Tang; Otto Walter; Azra Raza; Bruce Woda; Sa A Wang
Journal: Cancer Date: 2008-12-15 Impact factor: 6.860

Review 5. Treatment of myeloma: cure vs control.

Authors: S Vincent Rajkumar
Journal: Mayo Clin Proc Date: 2008-10 Impact factor: 7.616

6. Patient records at Mayo Clinic: lessons learned from the first 100 patients in Dr Henry S. Plummer's dossier model.

Authors: Christopher L Camp; Rory L Smoot; Theofilos N Kolettis; Cornelius B Groenewald; Susan M Greenlee; David R Farley
Journal: Mayo Clin Proc Date: 2008-12 Impact factor: 7.616

7. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal: Blood Date: 2007-09-24 Impact factor: 22.113

8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Authors: Erica D Warlick; Adina Cioc; Todd Defor; Michelle Dolan; Daniel Weisdorf
Journal: Biol Blood Marrow Transplant Date: 2009-01 Impact factor: 5.742

3. Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.

Authors: Motohiko Murase; Hiroyuki Iwamura; Kensuke Komatsu; Motoki Saito; Toshihiko Maekawa; Takaaki Nakamura; Takuya Yokokawa; Yasuhiro Shimada
Journal: Pharmacol Res Perspect Date: 2016-01-28

3 in total

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

1. Is "cure" essential in the treatment of cancer?

2. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.

4. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities.

Review 5. Treatment of myeloma: cure vs control.

6. Patient records at Mayo Clinic: lessons learned from the first 100 patients in Dr Henry S. Plummer's dossier model.

7. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

9. Clinical excellence in academia: perspectives from masterful academic clinicians.

10. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.

1. Bone marrow dyspoiesis associated with severe refractory anaemia in liver cirrhosis.

2. Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.

3. Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.